Clinical trial · Observational
Do Markers of Systemic Inflammatory Response and Tumor Metabolism Indicate Radioresistance in Head and Neck Cancer?
NCT05217212CI-TRIAL-00070360unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to prospectively evaluate whether markers of a patient's systemic inflammatory response in addition to FDG-PET/CT metabolic parameters of the primary tumor or of nodal metastases can predict radioresistance and survival before primary radiochemotherapy in advanced head and neck cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiochemotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Survival
- timeFrame
- Prospective analysis of various measures of survival up to 5 years after completion of the therapy. Events such as tumor recurrence or death will be recorded continually.
- description
- Overall survival, disease-specific survival, local and regional recurrence-free survival, and distant metastasis-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histopathologic diagnosis of squamous cell carcinoma of the head and neck * primary radio(chemo)therapy with curative intent * available pretherapeutic FDG-PET/CT imaging * available pretherapeutic differential blood analysis Exclusion Criteria: * other tumor entities of the head and neck including cutaneous squamous cell carcinoma * primary surgical treatment * ongoing infections or other inflammatory diseases at the time of diagnosis * patients not completing a course of irradiation with at least 66 Gray locally
References
Publications (0)
Data not yet available
No reference posted for this study.